國家衛生研究院 NHRI:Item 3990099045/13645

NHRI > National Institute of Infectious Diseases and Vaccinology > Ming-Hsi Huang > Periodical Articles > Item 3990099045/13645

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13645

Title:	Assessment of adjuvantation strategy of lipid squalene nanoparticles for enhancing the immunogenicity of a SARS-CoV-2 spike subunit protein against COVID-19
Authors:	Ho, HM;Huang, CY;Cheng, YJ;Shen, KY;Tzeng, TT;Liu, SJ;Chen, HW;Huang, CH;Huang, MH
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	Vaccination is regarded as the most effective intervention for controlling the coronavirus disease 2019 (COVID-19) pandemic. The objective of this study is to provide comprehensive information on lipid squalene nanoparticle (SQ@NP)-adjuvanted COVID-19 vaccines regarding modulating immune response and enhancing vaccine efficacy. After being adjuvanted with SQ@NP, the SARS-CoV-2 spike (S) subunit protein was intramuscularly (i.m.) administered to mice. Serum samples investigated by ELISA and virus neutralizing assay showed that a single-dose SQ@NP-adjuvanted S-protein vaccine can induce antigen-specific IgG and protective antibodies comparable with those induced by two doses of nonadjuvanted protein vaccine. When the mice received a boosting vaccine injection, anamnestic response was observed in the groups of adjuvanted vaccine. Furthermore, the secretion of cytokines in splenocytes, such as interferon (IFN)-γ, interleukin (IL)-5 and IL-10, was significantly enhanced after adjuvantation of S-protein vaccine with SQ@NP; however, this was not the case for the vaccine adjuvanted with conventional aluminum mineral salts. Histological examination of injection sites showed that the SQ@NP-adjuvanted vaccine was considerably well tolerated following i.m. injection in mice. These results pave the way for the performance tuning of optimal vaccine formulations against COVID-19.
Date:	2021-09-25
Relation:	International Journal of Pharmaceutics. 2021 Sep 25;607:Article number 121024.
Link to:	http://dx.doi.org/10.1016/j.ijpharm.2021.121024
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0378-5173&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000696634000002
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85113325074
Appears in Collections:	[Ming-Hsi Huang] Periodical Articles [Hsin-Wei Chen] Periodical Articles [Shih-Jen Liu] Periodical Articles [Tsai-Teng Tzeng] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP85113325074.pdf		2508Kb	Adobe PDF	183	View/Open

Loading...